Long-Term Follow-Up Data Support Longer RFS with Adjuvant Nivolumab Than with Ipilimumab in Patients with Melanoma at High Risk for Recurrence By Ogkologos - November 5, 2025 116 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the CheckMate 238 Source RELATED ARTICLESMORE FROM AUTHOR FX-909 Demonstrates Acceptable Safety and Preliminary Antitumour Activity, Establishing a Proof of Concept for PPARγ Inverse Agonism in Advanced Urothelial Cancer Pimicotinib Shows Robust Antitumour Activity and Clinically Meaningful Improvements in Patients with Tenosynovial Giant Cell Tumour FDA Grants Accelerated Approval to Zongertinib for Unresectable or Metastatic Non-Squamous NSCLC MOST POPULAR Does Sugar Feed Cancer? March 19, 2021 Tackling under-representation of Black data scientists in cancer research November 7, 2022 EMA Recommends Granting Marketing Authorisation for Efbemalenograstim Alfa February 12, 2024 The Nobel Prize in Chemistry 2020 was Awarded “for the Development... October 12, 2020 Load more HOT NEWS PAXG Significantly Improves EFS Compared with mFOLFIRINOX in Patients with Resectable... Dad Creates Inclusive Children’s Book For Daughter With Disability And Others... Bra Straps with Disappearing Message Remind Women to Check Their Breasts... Mutational Patterns Drive Metastatic Aggressiveness of Appendiceal Adenocarcinomas
